0000899243-20-030419.txt : 20201104
0000899243-20-030419.hdr.sgml : 20201104
20201104203720
ACCESSION NUMBER: 0000899243-20-030419
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201103
FILED AS OF DATE: 20201104
DATE AS OF CHANGE: 20201104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Roberts Christopher D.
CENTRAL INDEX KEY: 0001788368
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39200
FILM NUMBER: 201288328
MAIL ADDRESS:
STREET 1: C/O BLACK DIAMOND THERAPEUTICS, INC.
STREET 2: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc.
CENTRAL INDEX KEY: 0001701541
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-417-5868
MAIL ADDRESS:
STREET 1: 139 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aset Therapeutics, Inc.
DATE OF NAME CHANGE: 20170321
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-03
0
0001701541
Black Diamond Therapeutics, Inc.
BDTX
0001788368
Roberts Christopher D.
C/O BLACK DIAMOND THERAPEUTICS, INC.
139 MAIN STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Scientific Officer
Common Stock
2020-11-03
4
M
0
2500
10.86
A
2500
D
Common Stock
2020-11-03
4
S
0
2500
31.9492
D
0
D
Stock Option (Right to Buy)
10.86
2020-11-03
4
M
0
2500
0.00
D
2029-09-08
Common Stock
2500
186809
D
Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter.
/s/ Brent Hatzis-Schoch, as Attorney-in-Fact
2020-11-04